Soria LR, Gradilone SA, Larocca MC, Marinelli RA. Glucagon induces the gene expression of aquaporin-8 but not that of aquaporin-9 water channels in the rat hepatocyte. Am J Physiol Regul Integr Comp Physiol 296: R1274 -R1281, 2009. First published February 4, 2009 doi:10.1152/ajpregu.90783.2008.-Glucagon stimulates the vesicle trafficking of aquaporin-8 (AQP8) water channels to the rat hepatocyte canalicular membranes, a process thought to be relevant to glucagoninduced bile secretion. In this study, we investigated whether glucagon is able to modulate the gene expression of hepatocyte AQP8. Glucagon was administered to rats at 0.2 mg/100 g body wt ip in 2, 3, or 6 equally spaced doses for 8, 16, and 36 h, respectively. Immunoblotting analysis showed that hepatic 34-kDa AQP8 was significantly increased by 79 and 107% at 16 and 36 h, respectively. Hepatic AQP9 protein expression remained unaltered. AQP8 mRNA expression, assessed by real-time PCR, was not modified over time, suggesting a posttranscriptional mechanism of AQP8 protein increase. Glucagon effects on AQP8 were directly studied in primary cultured rat hepatocytes. Immunoblotting and confocal immunofluorescence microscopy confirmed the specific glucagon-induced AQP8 upregulation. The RNA polymerase II inhibitor actinomycin D was unable to prevent glucagon effect, providing additional support to the nontranscriptional upregulation of AQP8. Cycloheximide also showed no effect, suggesting that glucagon-induced AQP8 expression does not depend on protein synthesis but rather on protein degradation. Inhibitory experiments suggest that a reduced calpain-mediated AQP8 proteolysis could be involved. The action of glucagon on hepatocyte AQP8 was mimicked by dibutyryl cAMP and suppressed by PKA or phosphatidylinositol-3-kinase (PI3K) inhibitors. In conclusion, our data suggest that glucagon induces the gene expression of rat hepatocyte AQP8 by reducing its degradation, a process that involves cAMP-PKA and PI3K signal pathways.
aquaporins; protein kinase A; phosphatidylinositol-3-kinase; calpains; liver AQUAPORINS (AQPS) ARE A FAMILY of integral membrane proteins that facilitates the osmotic water movement across cellular membranes (27) . Four members of the AQP family are expressed in rat hepatocytes: AQP8 (5, 12, 16, 22) , AQP9 (13, 22) , AQP0 (22) , and AQP11 (17) . AQP8 is localized as a glycosylated 34-kDa protein in the canalicular plasma membrane domain (5, 12, 16, 22) and in intracellular vesicles (5, 12, 16, 22) and as a nonglycosylated 28-kDa protein in mitochondria (4) . There is experimental evidence suggesting that AQP8 facilitates the canalicular water transport during hepatocyte bile formation (22, 29, 37) and that the defective expression of hepatocyte AQP8 contributes to bile secretory dysfunction in cholestasis (8, 9, 31, 32) . The hormone glucagon stimulates hepatocyte bile formation (33) . Glucagon, via activation of PKA (19) and phosphatidylinositol-3-kinase (PI3K) (18) , induces AQP8 vesicle trafficking to the hepatocyte canalicular domain. Thus, glucagon increases the AQP-mediated osmotic membrane water permeability, facilitating the movement of water (18, 19) , a process likely to be relevant to glucagoninduced bile secretion.
Glucagon is known to exert pleiotropic actions on hepatocytes. Thus, in addition to the above-mentioned effects, glucagon has been reported to induce the hepatocyte gene expression of diverse proteins, including urea cycle enzymes (46) , gluconeogenic enzymes (25) , heme degradation enzymes (23) , drug-metabolizing enzymes (51) , signal transduction proteins (44) , gap junction proteins (28) , and proteins involved in cholesterol metabolism (39, 43) .
Therefore, the main goal of this study was to test whether glucagon is able to induce AQP8 expression in hepatocytes.
MATERIALS AND METHODS

Animals and treatments.
Adult male Wistar rats were maintained on a standard diet and water ad libitum, and they were housed in a temperature-and humidity-controlled environment under a constant 12:12-h light-dark cycle, according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health). Protocols were approved by local Animal Welfare Committee. Glucagon (Eli Lilly, Indianapolis, IN) was administered at 0.2 mg/100 g body wt ip in 2, 3, or 6 equally spaced doses for 8, 16 , and 36 h, respectively. Because of the short half-life of glucagon in plasma (41) , repetitive administrations are required for studies on long-term effects of glucagon. Under these conditions, glucagon was reported to induce hepatocyte alkaline phosphatase (2) . Control rats received only the glucagon vehicle (i.e., saline). After treatments, rats were anesthetized with ether and killed, and the livers were harvested for evaluation.
Alkaline phosphatase was assayed using a commercial kit (Wiener Laboratory, Rosario, Argentina), and the data were expressed as specific activity (mol nitrophenylphosphate hydrolyzed ⅐ min Ϫ1 ⅐ mg protein Ϫ1 ). Isolation, culture, and treatment of hepatocytes. Hepatocytes were isolated from normal livers of male Wistar rats by collagenase perfusion and mechanical disruption (16) . Cell viability (assessed by Trypan blue exclusion) was always greater than 85%. Freshly isolated hepatocytes were plated onto collagen-coated glass plates at 3.8 ϫ 10 4 cells/cm 2 , containing DMEM supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 g/ml) (Invitrogen, San Diego, CA). Our preliminary studies indicated that the addition of 10% FBS was required to stably maintain the AQP8 protein expression in culture rat hepatocytes. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 for 3 h, allowing cell attachment to plates.
After that time, medium was changed, and hepatocytes were incubated according to these protocols: 1) for 12 h in the presence of 0, 0.1, 0.5, or 1 M glucagon; 2) for 30 min in the presence of 10 g/ml actinomycin D (Fluka, St. Louis, MO) or vehicle and then for an additional 12 h in the presence of 0 or 1 M glucagon; 3) for 30 min in the presence of 5 g/ml cycloheximide (Sigma, St. Louis, MO) or vehicle and then for an additional 12 h in the presence of 0 or 1 M glucagon; 4) for 30 min in the presence of the lysosomal inhibitor leupeptin (250 M) (Chemicon, Temecula, CA) (31) or the proteasomal inhibitor MG132 (10 M) (Sigma) (31), or both in combination and then for additional 12 h in the presence of 0 or 1 M glucagon; 5) for 30 min in the presence of the calpain inhibitors N-acetyl-leucylleucyl-norleucinal (ALLN) (10 M) (Sigma) (30) Total hepatocyte membranes were prepared for immunoblotting studies. Treated hepatocytes exhibited no significant differences in cell viability, as determined by Trypan blue exclusion and by lactate dehydrogenase-release assays (47) . Protein contents after treatment and incubation were not different between control and treated cells.
Preparations of hepatic membrane fractions. Livers were homogenized by 15 up-down strokes with a loose fitting Dounce homogenizer in 4 volumes of 0.3 M sucrose, containing 0.1 mM phenylmethylsulfonyl fluoride (Sigma) and 0.1 mM leupeptin. Liver homogenates (or sonicated cultured hepatocytes) were subjected to low-speed centrifugation to obtain postnuclear supernatants, and then centrifuged at 200,000 g for 60 min, yielding total liver or total hepatocyte membranes (9) . Fractions enriched in plasma membranes were prepared from liver homogenates by centrifugation at 200,000 g for 60 min on a discontinuous 1.3 M sucrose gradient, as previously described by us (9) . The plasma membrane band was removed, diluted to 0.3 M, and centrifuged at 200,000 g for 60 min. This plasma membrane fraction was further purified by centrifugation at 100,000 g for 90 min on a continuous (9 -60%) sucrose gradient to yield the plasma membrane fraction. The enrichment and purity of liver plasma membranes, assessed by marker enzymes, were comparable to those reported previously by us (9) and similar between control and glucagon-treated rats. Proteins in membrane fractions were determined according to Lowry et al. (36) using BSA as a standard. Glucagon did not alter the yield of total proteins in liver or hepatocyte membrane fractions.
Real-time PCR analysis. Total RNA from livers of control and glucagon-treated rats were isolated by the TRIzol reagent (Invitrogen, San Diego, CA), according to the manufacturer's instructions. RNA concentration and purity were measured by UV spectrophotometry and cDNA was produced by using SuperScript II RNase H Ϫ reverse transcriptase (Invitrogen), according to the manufacturer's instructions. SYBR Green-based real-time RT-PCR analysis was employed to assess transcript levels; triplicate amplification reactions were performed with a Bio-Rad iCycler RT PCR machine (Bio-Rad Laboratories, Hercules CA). Primers used for detection of AQP8 were 5Ј-aagaccatgctgctaattcc-3Ј and 5Ј-tccacaatgacagagaaacc-3Ј and those for house keeping gene cyclophilin A were 5Ј-gcaagaccagcaagaaga-3Ј and 5Ј-agtgagagcagagattacag-3Ј. The size of the products amplified by each pair of primers were 275 and 153 bp, for AQP8 and cyclophilin A, respectively. At the end of these experiments, PCR products were removed from tubes and analyzed by gel electrophoresis to confirm their size. Quantification of the AQP8 mRNA in all samples was normalized to cyclophilin A, and the data were analyzed using the software iCycler IQ real-time PCR detection system.
Immunoblotting. Solubilized membrane fractions were subjected to 12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride membranes (NEN Life Science Products, Boston, MA). After blocking and washing, blots were incubated overnight at 4°C with rabbit affinity-purified antibodies against AQP8 or AQP9 (1 g/ml; Alpha Diagnostics International, San Antonio, TX) or for 1 h at room temperature with monoclonal anti-␤-actin (Sigma). The blots were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (DakoCytomation, Glostrup, Denmark). Protein bands were detected by enhanced chemiluminescence detection system (ECL; Amersham Pharmacia Biotech, Little Chalfont, Bucks, UK). Autoradiographs were obtained by exposing the membranes to Kodak XAR films (Eastman Kodak, Rochester, NY), and the bands were evaluated by densitometry using Gel-Pro32 software (Gel-Pro Analyzer, Media Cybernetics, Silver Spring, MD).
Immunofluorescence and confocal microscopy. After culture and treatment with 1 M glucagon for 12 h, hepatocytes were fixed with 2% paraformaldehyde for 10 min at room temperature, permeabilized and blocked with 0.2% Triton X-100/BSA 3% for 10 min, and incubated overnight at 4°C with rabbit affinity-purified AQP8 antibodies (10 g/ml; Alpha Diagnostics International, San Antonio, TX). After washing, we incubated coverslips with Alexa 488-conjugated goat anti-rabbit secondary antibody (Molecular Probes, Sunnyvale, CA) and Alexa 568 conjugated Phalloidin (Molecular Probes) for an additional hour. Coverslips were washed, incubated with DAPI (50 M) for 10 min, and mounted with ProLong (Molecular Probes). Fluorescence localization was detected by confocal microscopy (Nikon C1SiR with an inverted microscope Nikon TE200). Images were collected with the same confocal settings in each particular set of experiments. With these settings, no autofluorescence was detected. Controls using omission of primary or secondary antibodies revealed no labeling. Images were processed using Adobe Photoshop software.
Statistical analysis. Data are expressed as means Ϯ SE. Significance was determined using Student's t-test or the 1-way ANOVA, Tukey test; P Ͻ 0.05 was considered statistically significant.
RESULTS
In vivo effect of glucagon on liver AQP8 expression. Glucagon was administered to rats at 0.2 mg/100 g body wt ip for 8, 16 , and 36 h to investigate its effect on AQP8 expression. As reported previously (2), under those conditions, glucagon was able to significantly induce the specific activity of alkaline phosphatase in total liver membranes over 100% at each time, i.e., 8 h: 19 Ϯ 5 vs. 44 Ϯ 3; 16 h: 19 Ϯ 5 vs. 42 Ϯ 5; and 36 h: 29 Ϯ 6 vs. 75 Ϯ 9 (P Ͻ 0.05; n ϭ 3 or 4). Our immunoblotting studies indicated that glucagon caused a significant timedependent increase of liver 34-kDa AQP8 protein expression without altering that of liver 32 kDa AQP9 (Fig. 1, A and B) . Glucagon significantly increased AQP8 by 79% and 107% in total liver membranes at 16 and 36 h, respectively. We also observed the glucagon-increased AQP8 protein expression on the liver plasma membrane fraction (146% at 36 h; P Ͻ 0.05; n ϭ 4). However, AQP8 mRNA levels were not modified over time (Fig. 1A) , suggesting a posttranscriptional mechanism for glucagon-induced AQP8 protein upregulation.
Effect of glucagon on AQP8 expression in primary cultured hepatocytes. The action of glucagon on AQP8 expression was directly explored in primary cultured hepatocytes. In agreement with the in vivo data (see Fig. 1 ), exposure of cells to glucagon increased the expression of AQP8, without altering that of AQP9 (Fig. 2, A and B) . Glucagon (1 M) increased hepatocyte AQP8 by about 80% (Fig. 2A) . Confocal immunofluorescence studies showed that AQP8 labeling was stronger in glucagon-exposed hepatocytes (Fig. 3) . Together, these observations suggest that glucagon is also able to induce AQP8 protein expression in cultured rat hepatocytes.
Effect of actinomycin D and cycloheximide on the glucagoninduced AQP8 expression. To study the mechanisms involved in glucagon-induced AQP8 protein expression, we made use of the RNA polymerase II inhibitor, actinomycin D and the blocker of protein synthesis, cycloheximide. Fig. 4A shows that the action of glucagon on AQP8 expression was not prevented by actinomycin D, providing additional support to the nontranscriptional effect of the hormone. Cycloheximide (CHX) treatment was also unable to inhibit glucagon effect (Fig. 4B) , which suggests that glucagon-induced AQP8 expression does not depend on de novo protein synthesis. Treatment with actinomycin D (Fig. 4C) or cycloheximide (Fig. 4D ) was able to inhibit the increase of alkaline phosphatase specific activity, which was used as a positive control (2). Together, these data suggest the involvement of a diminished rate of proteolysis in the glucagon-induced AQP8 expression.
Effect of protease inhibitors on AQP8 protein expression in primary cultured hepatocytes.
To further explore the mechanisms of glucagon-induced AQP8 protein upregulation, we made use of the lysosomal, proteasomal, and calpain protease inhibitors. Lysosomal (leupeptin) and proteasomal (MG132) inhibitors, either alone (as we showed previously in Refs. 9 and 31) or in combination, did not alter basal hepatocyte AQP8 protein expression (Fig. 5) . Interestingly, we found that two different calpain inhibitors (ALLN and SJA7029) were able to increase significantly hepatocyte AQP8 protein levels (Fig. 5) . Moreover, we found that the treatment with ALLN and glucagon showed no additive effects on the increase of AQP8 levels (Fig. 5) .
These data suggest that calpains are important regulators of AQP8 protein expression in hepatocytes and that they could mediate glucagon action on AQP8.
Role of PKA and PI3K in the glucagon-induced hepatocyte AQP8 expression. We began to explore the signal transduction pathways involved in the glucagon-induced AQP8 expression by studying the role of PKA and PI3K. We found that the glucagon effect on hepatocyte AQP8 was mimicked by the cAMP analog dibutyryl cAMP (Fig. 6A ) and suppressed by two structurally different PKA inhibitors, H-89 and PKI (Fig.  6B) . To test the involvement of PI3K, we made use of two unrelated PI3K inhibitors, wortmannin and LY294002. Preincubation of the hepatocytes with either PI3K inhibitor mark- Fig. 3 . Effect of glucagon on hepatocyte AQP8 subcellular localization by confocal immunofluorescence. Primary cultured hepatocytes were incubated at 37°C for 12 h in the absence (control) or the presence of 1 M glucagon and analyzed for AQP8 subcellular localization, as described under MATERIALS AND METHODS. The figure shows the images obtained by immunofluorescence confocal microscopy for AQP8, actin, and the overlapping of AQP8 (in green), actin (in red), and nuclei (in blue). AQP8 was largely localized to cytoplasmic vesicular structures, as previously reported (16) . AQP8 labeling was stronger in glucagon-exposed hepatocytes. Scale bar ϭ 1 m. edly prevented the glucagon-induced expression of AQP8 in hepatocytes (Fig. 7) . These observations suggest that the glucagon-induced AQP8 upregulation in hepatocytes is dependent on the activation of cAMP-PKA and PI3K.
DISCUSSION
The major findings reported here relate to the hormonal regulation of AQP expression in hepatocytes. Our in vivo data in rats, as well as in primary cultured rat hepatocytes, suggest that glucagon induces the gene expression of rat hepatocyte AQP8 protein by reducing its degradation. Glucagon did not alter the protein expression of another member of the AQP family, i.e., AQP9, which suggests a specific effect of the hormone. Our results also suggest that the glucagon-induced AQP8 protein expression is dependent on cAMP-PKA and PI3K signaling pathways.
Glucagon has been reported to induce the expression of a variety of proteins in hepatocytes by transcriptional (23, 25, 28, 44, 46, 51) , as well as posttranscriptional (21, 39, 43) mechanisms. The fact that glucagon did not induce AQP8 mRNA expression in vivo and that the RNA polymerase II inhibitor actinomycin D was unable to prevent glucagon's effect in cultured hepatocytes suggests the nontranscriptional upregulation of hepatocyte AQP8. In addition, the glucagon-induced posttranscriptional processing of AQP8 does not seem to require de novo protein synthesis, as judged by our cycloheximide experiments. It is well established that in hepatocytes, glucagon activates adenylate cyclase and raises intracellular cAMP levels, which, in turn, activates PKA. Glucagon can also exert actions on hepatocytes that appear to occur independently of any increase in cAMP (1, 21) . Nevertheless, the results of our PKA inhibitory studies, together with the fact that the agonist dibutyryl cAMP is able to mimic glucagon effect, strongly suggest that glucagon induced AQP8 protein expression via a cAMP-dependent PKA signal transduction pathway. The AQP8 molecule lacks strong consensus PKA phosphorylation sites (24) , which suggests that the phosphorylationmediated signals are expected not to be directed toward AQP8 protein itself, but rather to unidentified protein mediators.
It has been shown that glucagon is able to induce PI3K activation in rat hepatocytes (55) . PI3K mediates several signaling transduction pathways in hepatocytes, including some involved in the regulation of vesicle trafficking and in the process of bile formation (3, 15, 38, 49) . In fact, we recently showed that PI3K, together with PKA, are involved in the glucagon-induced hepatocyte AQP8 trafficking (18) . Similarly, our data indicate the dual requirement of PKA and PI3K for glucagon-induced AQP8 hepatocyte expression. The cross-talk between PKA and PI3K signaling pathways in the upregulation of gene expression has also been found in nonhepatic cells (11, 45, 50, 54) . These observations may reflect the need for a cooperative action between PKA and PI3K on a single downstream effector. Consistent with this, it has been reported that in rat hepatocytes, cAMP can activate protein kinase B/Akt, a downstream PI3K effector (26, 49) . Interestingly, a cAMP-PKA-mediated phosphorylation of p85 regulatory subunit of PI3K has been suggested to be an important point of convergence of cAMP-PKA and PI3K signals (10) . Thus, it is tempting to speculate that the glucagon-induced AQP8 hepatocyte expression involves both the cAMP/PKA and PI3K signaling pathways in a cooperative manner.
Although the mechanisms underlying the posttranscriptional hepatocyte AQP8 stimulation by glucagon remain to be elucidated, these seem to be dependent on AQP8 protein degradation rather than altered protein synthesis, as suggested previously for glucagon-induced hepatocyte insulin-like growth factor binding protein-1 (21) . Our previous study (9, 31) , together with present data (Fig. 5) , suggests that a calpain, but not a lysosomal or a proteasomal, degradation pathway is involved in the control of basal levels of AQP8 protein expression in primary cultured hepatocytes. The fact that glucagon and calpain inhibitors showed no additive effect on AQP8 expression (Fig. 5) suggests that a glucagon-induced AQP8 upregulation by decreased rate of calpain-mediated proteolysis is conceivable. Although this issue requires further investigation, it is interesting to point out that the protein expression of another member of the AQP family, i.e., renal AQP2, has been recently found to be induced by glucagon (53) and that this AQP also undergoes degradation by calpains (42) .
The regulation of AQP gene expression seems to be species and/or cell-type specific. Thus, in human amnion-derived WISH cells, AQP8 protein and also mRNA expression are upregulated by cAMP (34, 48) . In porcine hepatocytes, AQP9 protein expression was found to undergo a mild increase (i.e., about 34%) by glucagon (6) .
In rodents subjected to fasting, a condition associated with increased circulating levels of glucagon, hepatic AQP8 is downregulated (14) , while AQP9 is upregulated (7) . Therefore, our present finding that glucagon per se is able to increase AQP8 expression without changing that of AQP9 would indicate that factors other than glucagon determine liver AQP expression during fasting.
Together, our previous (18, 19) and present data indicate that hepatocyte AQP8 is regulated by glucagon on a short-and long-term basis by stimulating its vesicle trafficking and gene expression, respectively. Interestingly, other AQP isoforms were also found to be modulated by both trafficking and gene expression, e.g., AQP2 in renal collecting duct principal cells by vasopressin (20, 40) and AQP5 in lung epithelial cells by cAMP (52) . Glucagon modulation results in an increased hepatocyte plasma membrane expression of AQP8, which facilitates osmotic membrane water transport (18, 19) , a process that is likely to be relevant to glucagon-induced bile formation (19) . Actually, there is experimental evidence suggesting that hepatocyte AQP8 facilitates the canalicular water transport during bile formation (22, 29, 37) and that the defective expression of hepatocyte AQP8 contributes to bile secretory dysfunction in cholestasis (8, 9, 31, 32) .
In conclusion, the results of this study suggest that glucagon induces the gene expression of rat hepatocyte AQP8 by reducing its degradation, a process that requires the activation of cAMP-PKA and PI3K signaling pathways.
Perspectives and Significance
Our in vivo and in vitro studies suggest that glucagon induces the gene expression of hepatocyte AQP8 via activation of cAMP-PKA and PI3K signaling pathways. Although the precise mechanisms by which glucagon exerts its action have not been determined, they seem to involve inhibition of calpain-mediated AQP8 protein degradation. This is a novel finding that warrants further investigation. The present observations, together with our previous studies, indicate that hepatocyte AQP8 is regulated by glucagon on a short-and longterm basis by stimulating its vesicle trafficking and gene expression, respectively. As AQP8 is a water channel that plays a key role in hepatocyte bile formation, this is likely to be relevant to glucagon-regulated bile secretion. Thus, our findings contribute to the understanding of regulatory and mechanistic aspects of hepatocyte AQP8 protein expression and bile formation.
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